Cargando…
Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study
BACKGROUND: Whole-genome sequencing (WGS) of Mycobacterium tuberculosis complex has become an important tool in diagnosis and management of drug-resistant tuberculosis. However, data correlating resistance genotype with quantitative phenotypic antimicrobial susceptibility testing (AST) are scarce. M...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436784/ https://www.ncbi.nlm.nih.gov/pubmed/35907429 http://dx.doi.org/10.1016/S2666-5247(22)00116-1 |
_version_ | 1784781449330688000 |
---|---|
author | Finci, Iris Albertini, Audrey Merker, Matthias Andres, Sönke Bablishvili, Nino Barilar, Ivan Cáceres, Tatiana Crudu, Valeriu Gotuzzo, Eduardo Hapeela, Nchimunya Hoffmann, Harald Hoogland, Christine Kohl, Thomas A Kranzer, Katharina Mantsoki, Anna Maurer, Florian P Nicol, Mark P Noroc, Ecaterina Plesnik, Sara Rodwell, Timothy Ruhwald, Morten Savidge, Theresa Salfinger, Max Streicher, Elizabeth Tukvadze, Nestani Warren, Robin Zemanay, Widaad Zurek, Anna Niemann, Stefan Denkinger, Claudia M |
author_facet | Finci, Iris Albertini, Audrey Merker, Matthias Andres, Sönke Bablishvili, Nino Barilar, Ivan Cáceres, Tatiana Crudu, Valeriu Gotuzzo, Eduardo Hapeela, Nchimunya Hoffmann, Harald Hoogland, Christine Kohl, Thomas A Kranzer, Katharina Mantsoki, Anna Maurer, Florian P Nicol, Mark P Noroc, Ecaterina Plesnik, Sara Rodwell, Timothy Ruhwald, Morten Savidge, Theresa Salfinger, Max Streicher, Elizabeth Tukvadze, Nestani Warren, Robin Zemanay, Widaad Zurek, Anna Niemann, Stefan Denkinger, Claudia M |
author_sort | Finci, Iris |
collection | PubMed |
description | BACKGROUND: Whole-genome sequencing (WGS) of Mycobacterium tuberculosis complex has become an important tool in diagnosis and management of drug-resistant tuberculosis. However, data correlating resistance genotype with quantitative phenotypic antimicrobial susceptibility testing (AST) are scarce. METHODS: In a prospective multicentre observational study, 900 clinical M tuberculosis complex isolates were collected from adults with drug-resistant tuberculosis in five high-endemic tuberculosis settings around the world (Georgia, Moldova, Peru, South Africa, and Viet Nam) between Dec 5, 2014, and Dec 12, 2017. Minimum inhibitory concentrations (MICs) and resulting binary phenotypic AST results for up to nine antituberculosis drugs were determined and correlated with resistance-conferring mutations identified by WGS. FINDINGS: Considering WHO-endorsed critical concentrations as reference, WGS had high accuracy for prediction of resistance to isoniazid (sensitivity 98·8% [95% CI 98·5–99·0]; specificity 96·6% [95% CI 95·2–97·9]), levofloxacin (sensitivity 94·8% [93·3–97·6]; specificity 97·1% [96·7–97·6]), kanamycin (sensitivity 96·1% [95·4–96·8]; specificity 95·0% [94·4–95·7]), amikacin (sensitivity 97·2% [96·4–98·1]; specificity 98·6% [98·3–98·9]), and capreomycin (sensitivity 93·1% [90·0–96·3]; specificity 98·3% [98·0–98·7]). For rifampicin, pyrazinamide, and ethambutol, the specificity of resistance prediction was suboptimal (64·0% [61·0–67·1], 83·8% [81·0–86·5], and 40·1% [37·4–42·9], respectively). Specificity for rifampicin increased to 83·9% when borderline mutations with MICs overlapping with the critical concentration were excluded. Consequently, we highlighted mutations in M tuberculosis complex isolates that are often falsely identified as susceptible by phenotypic AST, and we identified potential novel resistance-conferring mutations. INTERPRETATION: The combined analysis of mutations and quantitative phenotypes shows the potential of WGS to produce a refined interpretation of resistance, which is needed for individualised therapy, and eventually could allow differential drug dosing. However, variability of MIC data for some M tuberculosis complex isolates carrying identical mutations also reveals limitations of our understanding of the genotype and phenotype relationships (eg, including epistasis and strain genetic background). FUNDING: Bill & Melinda Gates Foundation, German Centre for Infection Research, German Research Foundation, Excellence Cluster Precision Medicine of Inflammation (EXC 2167), and Leibniz ScienceCampus EvoLUNG. |
format | Online Article Text |
id | pubmed-9436784 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-94367842022-09-09 Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study Finci, Iris Albertini, Audrey Merker, Matthias Andres, Sönke Bablishvili, Nino Barilar, Ivan Cáceres, Tatiana Crudu, Valeriu Gotuzzo, Eduardo Hapeela, Nchimunya Hoffmann, Harald Hoogland, Christine Kohl, Thomas A Kranzer, Katharina Mantsoki, Anna Maurer, Florian P Nicol, Mark P Noroc, Ecaterina Plesnik, Sara Rodwell, Timothy Ruhwald, Morten Savidge, Theresa Salfinger, Max Streicher, Elizabeth Tukvadze, Nestani Warren, Robin Zemanay, Widaad Zurek, Anna Niemann, Stefan Denkinger, Claudia M Lancet Microbe Articles BACKGROUND: Whole-genome sequencing (WGS) of Mycobacterium tuberculosis complex has become an important tool in diagnosis and management of drug-resistant tuberculosis. However, data correlating resistance genotype with quantitative phenotypic antimicrobial susceptibility testing (AST) are scarce. METHODS: In a prospective multicentre observational study, 900 clinical M tuberculosis complex isolates were collected from adults with drug-resistant tuberculosis in five high-endemic tuberculosis settings around the world (Georgia, Moldova, Peru, South Africa, and Viet Nam) between Dec 5, 2014, and Dec 12, 2017. Minimum inhibitory concentrations (MICs) and resulting binary phenotypic AST results for up to nine antituberculosis drugs were determined and correlated with resistance-conferring mutations identified by WGS. FINDINGS: Considering WHO-endorsed critical concentrations as reference, WGS had high accuracy for prediction of resistance to isoniazid (sensitivity 98·8% [95% CI 98·5–99·0]; specificity 96·6% [95% CI 95·2–97·9]), levofloxacin (sensitivity 94·8% [93·3–97·6]; specificity 97·1% [96·7–97·6]), kanamycin (sensitivity 96·1% [95·4–96·8]; specificity 95·0% [94·4–95·7]), amikacin (sensitivity 97·2% [96·4–98·1]; specificity 98·6% [98·3–98·9]), and capreomycin (sensitivity 93·1% [90·0–96·3]; specificity 98·3% [98·0–98·7]). For rifampicin, pyrazinamide, and ethambutol, the specificity of resistance prediction was suboptimal (64·0% [61·0–67·1], 83·8% [81·0–86·5], and 40·1% [37·4–42·9], respectively). Specificity for rifampicin increased to 83·9% when borderline mutations with MICs overlapping with the critical concentration were excluded. Consequently, we highlighted mutations in M tuberculosis complex isolates that are often falsely identified as susceptible by phenotypic AST, and we identified potential novel resistance-conferring mutations. INTERPRETATION: The combined analysis of mutations and quantitative phenotypes shows the potential of WGS to produce a refined interpretation of resistance, which is needed for individualised therapy, and eventually could allow differential drug dosing. However, variability of MIC data for some M tuberculosis complex isolates carrying identical mutations also reveals limitations of our understanding of the genotype and phenotype relationships (eg, including epistasis and strain genetic background). FUNDING: Bill & Melinda Gates Foundation, German Centre for Infection Research, German Research Foundation, Excellence Cluster Precision Medicine of Inflammation (EXC 2167), and Leibniz ScienceCampus EvoLUNG. Elsevier Ltd 2022-09 /pmc/articles/PMC9436784/ /pubmed/35907429 http://dx.doi.org/10.1016/S2666-5247(22)00116-1 Text en © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Articles Finci, Iris Albertini, Audrey Merker, Matthias Andres, Sönke Bablishvili, Nino Barilar, Ivan Cáceres, Tatiana Crudu, Valeriu Gotuzzo, Eduardo Hapeela, Nchimunya Hoffmann, Harald Hoogland, Christine Kohl, Thomas A Kranzer, Katharina Mantsoki, Anna Maurer, Florian P Nicol, Mark P Noroc, Ecaterina Plesnik, Sara Rodwell, Timothy Ruhwald, Morten Savidge, Theresa Salfinger, Max Streicher, Elizabeth Tukvadze, Nestani Warren, Robin Zemanay, Widaad Zurek, Anna Niemann, Stefan Denkinger, Claudia M Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study |
title | Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study |
title_full | Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study |
title_fullStr | Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study |
title_full_unstemmed | Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study |
title_short | Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study |
title_sort | investigating resistance in clinical mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436784/ https://www.ncbi.nlm.nih.gov/pubmed/35907429 http://dx.doi.org/10.1016/S2666-5247(22)00116-1 |
work_keys_str_mv | AT finciiris investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT albertiniaudrey investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT merkermatthias investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT andressonke investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT bablishvilinino investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT barilarivan investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT cacerestatiana investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT cruduvaleriu investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT gotuzzoeduardo investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT hapeelanchimunya investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT hoffmannharald investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT hooglandchristine investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT kohlthomasa investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT kranzerkatharina investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT mantsokianna investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT maurerflorianp investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT nicolmarkp investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT norocecaterina investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT plesniksara investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT rodwelltimothy investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT ruhwaldmorten investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT savidgetheresa investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT salfingermax investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT streicherelizabeth investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT tukvadzenestani investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT warrenrobin investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT zemanaywidaad investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT zurekanna investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT niemannstefan investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy AT denkingerclaudiam investigatingresistanceinclinicalmycobacteriumtuberculosiscomplexisolateswithgenomicandphenotypicantimicrobialsusceptibilitytestingamulticentreobservationalstudy |